← All tickers
JNJ
Johnson & Johnson0 mentions · 0 source(s) · avg NaN
Live
—
—
bid —ask —
Waiting for trade ticks (off-hours: only bid/ask updates).
知名基金持仓
Bridgewater Associates$170M
Price
$225.33
-5.47 (-2.37%)
Day Range
224.59–231.48
52w Range
149.04–251.71
Mkt Cap
$542.42B
Sector
Healthcare
Next Earnings
2026-07-15
Fwd P/E
17.7
Beta
0.26
Implied Move · 2026-06-05 (6.6d)
±2.25% ($220.25–$230.41)
ATM IV 19%
Generating AI analysis…
源:大 V
暂无大 V 提及(签名尚未计算)
源:细分
共 62 条(过去 30 天)
- news57
- research5
题材
Pharma
题材组
尚未归入题材组(签名缺失或提及不足)
SA 评级
更新于 21h agoQuant 评分
3.39
Hold
Wall St 共识
3.96
Buy
作者评级
3.50
Buy
作者评级分布(共 8 位)
SB 1B 3H 3S 1SS 0
Factor 评分
Growth
D-
D- · F
Profit
A+
A+ · A+
Momentum
B
B+ · B
Value
D-
D- · C
Revisions
B
A- · C
下方两个 = 3M / 6M 前
季节性
(窗口:10yr Avg) · 2 天前更新历史月均回报
+0.8%
1月
−0.8%
2月
+1.4%
3月
+0.9%
4月
−1.0%
5月
+1.4%
6月
+3.0%
7月
+0.3%
8月
−0.9%
9月
+0.4%
10月
+1.9%
11月
+1.0%
12月
上涨概率
73%
55%
64%
45%
40%
50%
80%
50%
40%
60%
60%
70%
内部人交易 (180天)
$0持平仅计 P/S
日期内部人动作股数价格总额
5月1日REED JOHN C · EVP, Innovative Medicine, R&D行权25,255$0.00$0
5月1日REED JOHN C · EVP, Innovative Medicine, R&DF11,002$229.85$2.53M
5月1日REED JOHN C · EVP, Innovative Medicine, R&D行权25,255$0.00$0
4月23日Woods Eugene A.授予975$0.00$0
4月23日West Nadja授予975$0.00$0
4月23日WEINBERGER MARK A授予975$0.00$0
4月23日Pinto Daniel E授予1,712$0.00$0
4月23日MORIKIS JOHN G授予1,540$0.00$0
4月23日McClellan Mark B.授予975$0.00$0
4月23日Joly Hubert授予975$0.00$0
4月23日Johnson Paula A授予975$0.00$0
4月23日HEWSON MARILLYN A授予975$0.00$0
4月23日Doudna Jennifer A授予975$0.00$0
4月23日Beckerle Mary C授予975$0.00$0
源:X 实时
实时数据暂不可用
Research · 5
- 行业4天前日本制药参观：生物制药行业的关键横向启示日本制药参观带来的生物制药行业横向启示
- 行业5月22日美国生物制药行业新药上市追踪：多款新药早期处方量未达共识预期美国生物制药行业新药上市初期表现与竞争格局分析
- 行业5月15日IQVIA处方数据揭示美国生物药市场：新药放量不及预期，生物类似药持续替代基于IQVIA处方数据分析美国药物市场新药上市初期放量情况及生物类似药竞争格局
- 行业5月8日IQVIA处方数据追踪美国生物制药：新药上市表现与生物类似药竞争格局通过IQVIA处方数据分析美国生物制药市场核心药物动态和竞争格局
- 行业5月1日美国生物制药新药上市处方量普遍不及共识，品牌药因回扣结构韧性超预期新药上市初期处方量普遍低于实现营收共识所需路径，生物类似药对品牌药侵蚀慢于预期
Headlines · 15 from sa_press_release
- sa_press_release11hRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- sa_news15hFDA to cut animal testing in cancer drug development
- sa_press_release17hNew TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- sa_news18hJ&J granted Tremfya label expansion for joint damage in psoriatic arthritis
- seekingalpha_rss18hJ&J granted Tremfya label expansion for joint damage in psoriatic arthritis
- seekingalpha_rssauthor:Busted IPO Forum18hCompass Pathways: A Psychedelics Story
- sa_press_release1dFDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- seekingalpha_rssauthor:Brett Ashcroft Green1dBuilding A $100,000 All-Weather Dividend Portfolio For May 2026
- seekingalpha_rssauthor:Brett Ashcroft Green1dBuilding A $100,000 All-Weather Dividend Portfolio For May 2026
- sa_press_release2dJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- seekingalpha_rssauthor:Baron Capital2dBaron Health Care Fund Q1 2026 Portfolio Activity
- seekingalpha_rssauthor:Baron Capital2dWhy We Increased The Position In Johnson & Johnson
- seekingalpha_rssauthor:SA Transcripts2dJohnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
- seekingalpha_rssauthor:Dividend Yield Theorist2dBest Dividend Aristocrats: May 2026
- seekingalpha_rssauthor:Stefan Redlich3dMy Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys